P&T News: December 1994, Vol. 15, No. 6
Pharmacy and Therapeutics Subcommittee of the University
Hospital Advisory Committee and the Pharmcy Department
Peer Review Status: Internally Peer Reviewed
Several key points should be noted regarding appropriate use of the table:
1. The doses listed are for moderate to severe infections; higher doses may be required for life-threatening infections; lower doses can be utilized for urinary tract infections.
2. No dosage reductions are required for loading doses.
3. Select drugs (e.g., aminoglycosides, amphotericin B) may cause nephrotoxicity; thus, they may be a causative factor in a patient with rapidly declining renal function.
|
Guide for Injectable Antibiotic Dosing in Adults with Renal Dysfunction[1] | |||||
|
Drug |
Normal dose[1] |
ClCr[2] 80-50 ml/min |
ClCr[2] 49-30 ml/min |
ClCr[2] 29-10 ml/min |
Clcr[2] less than 10 ml/min |
|
Cephalosporins |
|
|
|
| |
|
Cefazoline |
1-2 Gm q8h |
[3] |
0.5-1 Gm q8h |
0.5-1 Gm q12h |
0.5-1 Gm q24h |
|
Cefoxitin |
1-2 Gm q6-8h |
[3] |
1-2 Gm q8-12h |
1-2 Gm q12-24h |
0.5-1 Gm q12-24h |
|
Cefotaxime |
1-2 Gm q8h |
[3] |
[3] |
0.5-1 Gm q8-12h |
1 Gm q24h |
|
Ceftriaxone |
1-2 Gm q24h |
[3] |
[3] |
[3] |
[3] |
|
Ceftazidime (P) |
1-2 Gm q8h |
[3] |
1 Gm q12h |
1 Gm q24h |
0.5 Gm q24h |
|
Penicillins |
|
|
|
|
|
|
Penicillin G |
2 MU q4h |
[3] |
[3] |
1 MU q4h |
1 MU q8-12h |
|
Nafcillin |
1-2 Gm q4-6h |
[3] |
[3] |
[3] |
[3] |
|
Ampicillin |
1-2 Gm q4-6h |
[3] |
[3] |
1-2 Gm q8h |
1-2 Gm q12h |
|
Ampicillin-Sulbactam (P) |
1.5-3 Gm q6h |
[3] |
1.5-3 Gm q6-8h |
1.5-3 Gm q12h |
1.5-3 Gm q24h |
|
Piperacillin (P) |
3 Gm q6h |
[3] |
[3] |
3 Gm q8h |
3 Gm q12h |
|
Piperacillin-Tazobactam (P) |
3.375 Gm q6h |
[3] |
2.25 Gm q6h |
2.25 Gm q8h |
2.25 Gm q8h |
|
Ticarcillin-Clavulanate (P) |
3.1 Gm q6h |
[3] |
3.1 Gm q6-8h |
3.1 Gm q8-12h |
3.1 Gm q24h |
|
Aminoglycosides |
|
|
|
| |
|
Amikacin[5] (P) |
7.5 mg/kg q12h |
[3] |
[3] |
7.5 mg/kg q24h |
7.5 mg/kg q48h |
|
Gentamicin[5] |
1 mg/kg q8h |
[3] |
1 mg/kg q12h |
1 mg/kg q12-24h |
1 mg/kg q24-48h |
|
Tobramycin[5] (P) |
1 mg/kg q8h |
[3] |
1 mg/kg q12h |
1 mg/kg q12h-24 |
1 mg/kg q24-48h |
|
Antifungals |
|
|
|
| |
|
Amphotericin B[5] |
0.5-1 mg/kg q24h |
[3] |
[3] |
[3] |
[3] |
|
Fluconazole |
100-200 mg q24h |
[3] |
50-100 mg q24h |
50 mg q24h |
50 mg q24h |
|
Antivirals |
|
|
|
|
|
|
Acyclovir |
5 mg/kg q8h |
[3] |
5 mg/kg q12h |
5 mg/kg q24h |
2.5 mg/kg q24h |
|
Ganciclovir |
5 mg/kg q12h |
2.5 mg/kg q12h |
2.5 mg/kg q24h |
1.25 mg/kg q24h |
1.25 mg/kg q24h |
|
Miscellaneous |
|
|
|
| |
|
Erythromycin |
0.5-1 Gm q6h |
[3] |
[3] |
[3] |
[3] |
|
Trimethoprim/Sulfamethoxazole[6] |
2.5-7.5 mg/kg q6-12h |
[3] |
2.5-7.5 mg/kg q12h |
2.5-5 mg/kg q12h |
2.5-5 mg/kg q24h |
|
Aztreonam (P) |
1-2 Gm q8-12h |
[3] |
1-2 Gm q12h |
0.5-1 Gm q8-12h |
0.5-1 Gm q12-24h |
|
Ciprofloxacin (P) |
200-400 mg q12h |
[3] |
[3] |
200-400 mg q12-24h |
200-400 mg q24h |
|
Clindamycin |
300-900 mg q8h |
[3] |
[3] |
[3] |
[3] |
|
Imipenem-Cilastatin (P) |
0.5-1 Gm q6h |
0.5 Gm q6-8H |
0.5 Gm q6-8h |
0.5 Gm q8-12h |
0.25-0.5 Gm q12h |
|
Metronidazole |
500 mg q6h |
[3] |
[3] |
[3] |
[3] |
|
Pentamidine |
300 mg q24h |
[3] |
[3] |
300 mg q24-36h |
300 mg q48h |
|
Vancomycin |
1 Gm q12h |
1 Gm q12-24h |
0.75 Gm q12-24h |
0.5 mg q12-24h |
0.5 Gm q5 days |
|
[1] Dosage for moderate to severe infections; higher doses may be required for life threatening infections; lower doses may be utilized for UTI. [2] ClCr = Creatinine Clearance [3] No reduction from normal dose necessary [4] UIHC Protocol drug [5] These agents can cause nephrotoxicity, and may be the causative agent in patients with rapidly declining renal function. [6] Based on trimethoprim component Note: No dosage reduction is required for loading doses. | |||||
Drugs Added to Stock
BORIC ACID VAGINAL CAPSULES: 600 mg Boric acid vaginal capsules (extemporaneously compounded) are used for the treatment of refractory vaginal yeast infections caused by Torulopsis glabrata.
CHLORHEXIDINE OPHTHALMIC SOLUTION: 0.02% Chlorhexidine (extemporaneously compounded) ophthalmic solution is used for the adjunctive treatment of Acanthamoeba keratitis.
EPINEPHRINE INJECTION: 0.15 MG/0.3 ML (1:2000), AUTO-INJECTOR
This product (EpiPen J® - Center Labs) is used for the emergency treatment of severe acute anaphylactic reactions in pediatric patients.
LEVOTHYROXINE TABLETS: 0.05 mg Levothyroxine is used as a replacement or supplemental therapy in hypothyroidism.
MORPHINE SULFATE ORAL SOLUTION: 20 mg/ml, 120 ml; INTRATHECAL INJECTION: 50 mg/ml, 10 ml VIAL Morphine sulfate is indicated for the management of pain.
PILOCARPINE TABLETS: 5 mg Pilocarpine tablets (Salagen® - MGI Pharma) are indicated for treatment of xerostomia from salivary gland hypofunction caused by radiation therapy for cancer of the head and neck.
SQUARIC ACID DIBUTYLESTER TOPICAL SOLUTION: 0.01%, 0.1%, 2% This extemporaneously compounded solution is used for the treatment of alopecia areata.
Drugs Deleted from Stock
NICLOSAMIDE (Niclocide®) 500 mg TABLETS Discontinued by the manufacturer.
EPINEPHRINE 0.1% (1:1000) OPHTHALMIC SOLUTION Discontinued by the manufacturer.
Labeling Change
ALUMINUM HYDROXIDE CAPSULES Aluminum hydroxide capsules (Alu-Cap®) are now labeled as containing 400 mg of aluminum hydroxide. The capsules had previously been labeled as 475 mg which is the weight of hydrated aluminum hydroxide. New labeling requirements stipulate that the strength now be reported as the unhydrated aluminum hydroxide component. The formulation of the capsules remains the same.